The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
Main Authors: | Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado: |
BMC
2025-01-01
|
Series: | BMC Complementary Medicine and Therapies |
Subjects: | |
Acceso en liña: | https://doi.org/10.1186/s12906-025-04753-w |
Títulos similares
-
Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis
por: Ana Pilar Pérez-Acevedo, et al.
Publicado: (2020-12-01) -
Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)
por: Elmar Graessel, et al.
Publicado: (2024-10-01) -
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
por: Anna Gościniak, et al.
Publicado: (2024-11-01) -
Cannabis Contaminants Limit Pharmacological Use of Cannabidiol
por: Zackary Montoya, et al.
Publicado: (2020-09-01) -
El cannabidiol y sus indicaciones en psiquiatría
por: Juan Fernando Muñoz Ramírez
Publicado: (2021-03-01)